Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients

Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients

Circulating tumor DNA can be used to monitor the treatment effect and identify developing resistance mutations during ALK directed TKI treatment.

The purpose and objectives of the non-interventional study with primary data collection is

• To determine if monitoring the amount of translocated DNA in the blood reflects alectinib treatment effect.
• To assess the presence and type of resistance mutations using ctDNA at the time patients experience clinical progression on alectinib.
• To investigate if the resistance mutations identified at clinical progression could have been identified in blood samples taken before clinically evident progression.

Inclusion Criteria:

1. Patients with ALK translocated metastatic NSCLC, treated with alectinib as 1st line therapy in routine clinical practice
2. Written (personally dated and signed) informed consent

Exclusion Criteria: